AstraZeneca And The SEC's Focus On Life Sciences

Law360, New York (September 9, 2016, 11:49 AM EDT) -- Gary F. Giampetruzzi

S. Joy Dowdle

Katherine K. Solomon Continuing its onslaught of enforcement actions against life sciences companies this year, the U.S. Securities and Exchange Commission announced its recent settlement with AstraZeneca PLC. The Aug. 30, 2016, cease-and-desist order resolves allegations that AstraZeneca's Chinese and Russian subsidiaries violated the internal controls and recordkeeping requirements of the Foreign Corrupt Practices Act, which allowed management and staff to engage in and conceal improper payment schemes to health care providers ("HCPs") at state-owned and state-controlled entities in China and Russia and to local government officials in China. AstraZeneca paid $4,325,000 in profit disgorgement,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!